Laseroptek Obtains MFDS Approval for Next-Generation Vascular Laser "Baseukyura589"
Laseroptek, a company specializing in laser devices for skin beauty and dermatologic disease treatment, announced on the 10th that it has obtained item approval from the Ministry of Food and Drug Safety for its new product, Baseukyura589.
Baseukyura589 is the world's first solid-state vascular treatment laser device that implements a 589-nanometer wavelength based on Raman technology. It is designed for broad use not only in treating vascular skin diseases such as hemangioma, port-wine stains, rosacea, and facial flushing, but also in various vascular pigment treatments and aesthetic procedures including melasma, hyperpigmentation, and toning. Compared with conventional pulsed dye lasers, it enhances output stability and improves maintenance efficiency by eliminating the need for consumable dye replacement, thereby increasing both clinical safety and treatment efficiency.
Laseroptek regards Baseukyura589 as a "10-year growth engine" that will drive its mid- to long-term expansion. The company plans to first establish Baseukyura589 successfully in the disease treatment market and then expand its scope into the aesthetic dermatology market. It is currently undergoing the approval process with the U.S. Food and Drug Administration (FDA), and global market entry is expected to become visible as early as the second half of this year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Changjin, CEO of Laseroptek, said, "Baseukyura589 is an innovative device that will present a new paradigm in the vascular treatment market," adding, "Even at this stage, as we prepare for its launch with technology that can overcome the limitations of existing pulsed dye lasers, there is already strong interest from the medical community both in Korea and overseas."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.